Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

OM-85 BV: primary versus secondary prevention

J P Collet1, J P Boissel

  • 1Unité de Pharmacologie Clinique, Université Claude-Bernard, Lyon, France.

Respiration; International Review of Thoracic Diseases
|January 1, 1994
PubMed
Summary

Immunoactive bacterial extracts like OM-85 BV show promise in preventing recurrent respiratory infections in children. While not effective for primary prevention in day-care settings, it may reduce infection episodes, particularly in younger children.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014-2019).

Frontiers in cardiovascular medicine·2023
Same author

Universal screening of newborns for biliary atresia: Cost-effectiveness of alternative strategies.

Journal of medical screening·2019
Same author

Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR).

Anaesthesia, critical care & pain medicine·2018
Same author

Home-based screening for biliary atresia using infant stool colour cards: a large-scale prospective cohort study and cost-effectiveness analysis.

Journal of medical screening·2014
Same author

Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.

European heart journal·2013
Same author

Optimal time for catheterization in NSTE-ACS patients with impaired renal function: insights from the ABOARD Study.

International journal of cardiology·2012

Area of Science:

  • Pediatrics
  • Immunology
  • Infectious Diseases

Background:

  • Recurrent upper respiratory tract infections (URTIs) in children significantly impact quality of life and incur substantial costs.
  • Specific vaccines for common URTI pathogens are lacking, necessitating alternative preventive strategies.
  • Immunoactive bacterial extracts (IBEs) stimulate the non-specific immune system against various pathogens.

Purpose of the Study:

  • To evaluate the efficacy of OM-85 BV, an IBE, as a primary preventive agent against recurrent URTIs in children attending day-care centers.
  • To assess the secondary preventive effect of OM-85 BV in children with a history of repeated infections.

Main Methods:

  • A study involving children in day-care centers to assess primary prevention over 7.5 months.

Related Experiment Videos

  • An exploratory analysis focusing on a 3-month treatment period and correlation with age.
  • Comparison of URTI episode frequency between OM-85 BV and placebo groups.

    • Main Results:

    • OM-85 BV did not demonstrate significant efficacy in primary prevention of recurrent URTIs over 7.5 months (RR 0.79, CI 0.59-1.06).
    • An exploratory analysis revealed a 48% risk reduction for >= 3 episodes during a 3-month treatment period.
    • Drug efficacy showed a strong correlation with the age of the children in the exploratory analysis.

    Conclusions:

    • OM-85 BV is effective for secondary prevention of recurrent airway infections in children.
    • Its efficacy as a primary preventive agent in high-risk environments like day-care centers requires further investigation.
    • Age appears to be a significant factor influencing the effectiveness of OM-85 BV.